Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
Invivyd announced that its investigational monoclonal antibody, VYD222 (pemivibart), shows continued in vitro neutralizing activity against the current dominant SARS-CoV-2 variants, KP.1.1 FLiRT and KP.3.
This data aligns with earlier findings from an independent lab. The next candidate, VYD2311, also shows similar neutralization activity. As of June 8, 2024, FLiRT variants account for over 50% of circulating SARS-CoV-2 sequences, with KP.3 expected to become the most dominant strain.
Invivyd uses proprietary software, VivydTools, to track and monitor virus variations. The company notes the stability of the VYD222 epitope and is committed to ongoing assessment.
- VYD222 shows continued in vitro neutralizing activity against dominant SARS-CoV-2 variants KP.1.1 FLiRT and KP.3.
- Next mAb candidate, VYD2311, also demonstrates neutralizing activity against these strains.
- FLiRT variants account for over 50% of circulating SARS-CoV-2 sequences as of June 8, 2024.
- CDC predicts KP.3 will become the most dominant SARS-CoV-2 lineage nationally.
- VYD222 epitope shows a high stability with 99.8% conservation in 2024 sequences.
- No observed changes in the binding interface for KP.1.1 FLiRT and KP.3 variants.
- Invivyd employs proprietary software, VivydTools, for virus variant tracking and early detection.
- The data presented is from in vitro studies, which may not fully translate to clinical efficacy.
- No details provided on the timeline for clinical trials or market availability of VYD222 and VYD2311.
- Dependence on in-house software, VivydTools, may limit external validation of findings.
Insights
The latest announcement from Invivyd regarding the antiviral activity of VYD222 against emerging SARS-CoV-2 variants is a significant development in the ongoing fight against COVID-19. Monoclonal antibodies (mAbs) like VYD222 are lab-engineered molecules that can bind to specific parts of viruses, neutralizing their ability to infect cells.
The data presented shows that VYD222 retains neutralizing activity against the KP.1.1 FLiRT and KP.3 variants, which are currently predominant strains. This consistent neutralizing ability is crucial, as the virus continues to evolve, making some previous therapies less effective or obsolete. The robust stability of the VYD222 epitope, as evidenced by the 99.8% sequence conservation, is a critical finding, suggesting that this mAb may have enduring efficacy even as the virus mutates.
In vitro data, while promising, need to be supplemented with clinical trials to confirm effectiveness in humans. Success in these assays generally predicts good potential for clinical efficacy, but the transition from lab to patient can present unforeseen challenges. The broader impact on public health and the potential role of VYD222 in treatment protocols will depend on these further tests.
From a market perspective, the announcement by Invivyd is poised to have a positive impact on their stock. Investors often respond favorably to news of potential breakthroughs in treating or preventing diseases, particularly a high-profile illness like COVID-19. The continued neutralization activity against the KP.1.1 FLiRT and KP.3 variants positions Invivyd favorably among its competitors.
The mention of proprietary software, VivydTools, underscores Invivyd's ongoing commitment to staying ahead in antiviral research. This technological edge could enhance their ability to rapidly adapt to new variants, ensuring the relevance and efficacy of their products. Investors should watch for upcoming clinical trial results, regulatory approvals and potential market penetration of these therapies.
Given the increasing prevalence of the KP.3 variant and the CDC's prediction of its dominance, Invivyd's proactive stance and favorable preliminary data could lead to increased market confidence and potentially drive stock prices up, at least in the short term. However, investors should remain cautious and look for concrete clinical trial outcomes and real-world efficacy data before making long-term investment decisions.
Focusing on the financial aspects, Invivyd's report of VYD222's potential effectiveness against new COVID-19 variants is likely to bolster investor confidence. This news can have immediate positive short-term effects on the company's stock price due to the optimistic outlook it presents. However, the true financial impact will depend on subsequent clinical trial results, potential FDA approvals and eventual market uptake.
Investors should keep an eye on the company's research and development (R&D) expenditure and any upcoming funding rounds or partnerships that could support the progression of VYD222 and VYD2311 to market. Successful clinical trials could lead to lucrative contracts with governments and health organizations, significantly boosting revenue streams.
Another factor to consider is the competitive landscape. While Invivyd's data is promising, other companies are also racing to develop effective treatments for COVID-19. It will be important to monitor how Invivyd positions itself against competitors and whether it can maintain a technological edge through innovations like VivydTools.
The long-term financial health of Invivyd will be closely tied to the sustained efficacy of its mAbs against evolving SARS-CoV-2 variants and the company's ability to navigate the complex regulatory landscape efficiently.
- Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and the most recent FLiRT-containing viruses
- Invivyd’s new data is broadly concordant with preliminary pseudovirus data showing neutralizing activity of VYD222 against KP.2 FLiRT and KP.3 variants recently publicized by an independent academic lab
- Invivyd’s next anticipated SARS-CoV-2 monoclonal antibody (mAb) candidate, VYD2311, also shows continued in vitro neutralization activity in pseudovirus assays against these predominant strains to date
WALTHAM, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that VYD222 (pemivibart), a half-life extended investigational monoclonal antibody (mAb), shows continued in vitro neutralization activity in pseudovirus assays designed to represent the predominant emerging variants of SARS-CoV-2, including the KP.1.1 FLiRT and KP.3 variants. FLiRT variants account for over half of circulating SARS-CoV-2 variant sequences for the two-week period ending June 8, 2024, with KP.3 prevalence increasing and the Centers for Disease Control and Prevention (CDC) predicting it will become the most dominant SARS-CoV-2 lineage nationally in the near term. Of note, VYD222 has previously demonstrated antiviral in vitro neutralization activity against ancestral XBB lineage viruses that also encoded mutations described in the FLip and FLiRT nomenclature.
“The VYD222 epitope has remained stable with a calculated
Invivyd continually monitors the SARS-CoV-2 variant landscape using VivydTools, its in-house proprietary software that tracks virus variation across SARS-CoV-2, towards enabling early detection and characterization of neutralization activity of emergent variants, including FLiRT variants.
About VYD222
VYD222 is a half-life extended monoclonal antibody (mAb) candidate being investigated for the pre-exposure prophylaxis (prevention) of COVID-19 and the treatment of mild to moderate symptomatic COVID-19 in certain immunocompromised adults and adolescents. VYD222 has demonstrated in vitro neutralizing activity in pseudotyped virus-like particle and authentic virus neutralization assays against various pre-Omicron and Omicron variants, including JN.1. VYD222 was engineered from adintrevimab, Invivyd’s investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in global Phase 2/3 clinical trials for both the prevention and treatment of COVID-19. VYD222 has not been approved by the U.S. FDA or any other regulatory authority.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could,” “expects,” “intends,” “potential,” “predicts,” “projects,” and “future” or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the continued neutralization activity of VYD222 and VYD2311 against dominant SARS-CoV-2 variants, including KP.1.1 and KP.3; predictions regarding the future of the SARS-CoV-2 variant landscape and the company’s plans to monitor such landscape using its in-house proprietary software designed towards enabling early detection and characterization of neutralization activity of emerging variants; the company’s devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; the design of the company’s INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to keep pace with evolving viral threats; the company’s plans for a series of innovative antibody candidates; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company’s forward-looking statements and you should not place undue reliance on the company’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: whether VYD222, VYD2311 or any other product candidate is able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; variability of results in models used to predict activity against SARS-CoV-2 variants; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; whether the company is able to successfully submit any future EUA request to the FDA, and the timing, scope and outcome of any such EUA request; uncertainties related to the regulatory authorization or approval process; changes in the regulatory environment; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of any product candidate following regulatory authorization or approval; the timing and progress of the company’s discovery, preclinical and clinical development activities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company’s product candidates based on neutralizing activity; the risk that results of preclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; the company’s reliance on third parties with respect to virus assay creation and product candidate testing and with respect to its clinical trials; changes in expected or existing competition; the complexities of manufacturing mAb therapies; the company’s ability to leverage its INVYMAB platform approach to facilitate the rapid, serial generation of new mAbs to keep pace with evolving viral threats; any litigation and other proceedings or government investigations relating to the company; the company’s ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC), and in the company’s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-1747
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
What is VYD222?
What are the KP.1.1 FLiRT and KP.3 variants?
How effective is VYD222 against the latest COVID-19 variants?
What is Invivyd's next monoclonal antibody candidate?
How does Invivyd track SARS-CoV-2 variants?
What is the significance of FLiRT variants in SARS-CoV-2?
